Keywords: corcept, corlux, misses, ph, iii, endpoint, pmd
Corcept's Corlux misses Ph III endpoint in PMD
Article | 26 March 2007
US drugmaker Corcept Therapeutics says that Study 06, the last of three Phase III trials evaluating its lead drug candidate Corlux ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
